RESHAPE LIFESCIENCES INC (RSLS) Stock News
NASDAQ:RSLS - Nasdaq - US76090R3093 - Common Stock - Currency: USD
RSLS Latest News, Press Relases and Analysis
Here are the top movers in Monday's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Most active stocks in Monday's session
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without...
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device...
ReShape Lifesciences Ignites Retail Frenzy As Stock Soars On US Patent For Diabetes Neuromodulation System
The technology leverages ReShape’s proprietary vagus nerve block and stimulation platform to regulate blood glucose in patients with Type 2 diabetes by modulating nerve signals to the liver and pancreas.
Top movers analysis in the middle of the day on 2025-04-21: top gainers and losers in today's session.
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
The market is filled with gapping stocks in Monday's session.
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Patent Enables Equivalent Efficacy with 10 times Lower Energy...
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
ReShape Enters Exclusive U.S. Distribution Agreement in the Neuromuscular Rehabilitation Market
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
ReShape Enters Exclusive U.S. Distribution Agreement in the Neuromuscular Rehabilitation Market...
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
Significant Reduction in Overall Operating Expenses of 41.9% in 2024, Excluding M&A Related Expenses, Compared to 2023 Merger Agreement With Vyome...